Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042)
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
- Status
- COMPLETED
- Phase
- PHASE3
Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)
- Status
- TERMINATED
- Phase
- PHASE1
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Intraoperative Neuromuscular Blockade and Postoperative Atelectasis
- Status
- COMPLETED
- Phase
- N/A
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)
- Status
- COMPLETED
- Phase
- PHASE3
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- Status
- RECRUITING
- Phase
- PHASE3
V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)
- Status
- COMPLETED
- Phase
- PHASE2
BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab
- Status
- COMPLETED
- Phase
- PHASE1